Bu sayfanın çevirisi deneyseldir ve geliştirilme aşamasındadır. imlerinizi bekliyoruz!

Monopar Therapeutics Bilanço Sağlığı

Finansal Sağlık kriter kontrolleri 5/6

Monopar Therapeutics şirketinin toplam hissedar öz sermayesi $6.1M ve toplam borcu $0.0 olup, bu da borç-öz sermaye oranını 0% seviyesine getiriyor. Toplam varlıkları ve toplam yükümlülükleri sırasıyla $7.2M ve $1.1M dir.

Anahtar bilgiler

Borç/özkaynak oranı

US$0

Borç

Faiz karşılama oranı	n/a
Nakit	US$7.12m
Eşitlik	US$6.09m
Toplam yükümlülükler	US$1.09m
Toplam varlıklar	US$7.18m

Son finansal sağlık güncellemeleri

We Think Monopar Therapeutics (NASDAQ:MNPR) Needs To Drive Business Growth Carefully

Aug 13

Is Monopar Therapeutics (NASDAQ:MNPR) In A Good Position To Deliver On Growth Plans?

Feb 27

Recent updates

We Think Monopar Therapeutics (NASDAQ:MNPR) Needs To Drive Business Growth Carefully

Aug 13

Is Monopar Therapeutics (NASDAQ:MNPR) In A Good Position To Deliver On Growth Plans?

Feb 27

Will Monopar Therapeutics (NASDAQ:MNPR) Spend Its Cash Wisely?

Mar 02

We Think Monopar Therapeutics (NASDAQ:MNPR) Needs To Drive Business Growth Carefully

Nov 16

Monopar stock soars 19% as enrollment finishes in phase 2 part of oral mucositis study of Validive

Oct 05

We're Keeping An Eye On Monopar Therapeutics' (NASDAQ:MNPR) Cash Burn Rate

Jul 30

Monopar Therapeutics (NASDAQ:MNPR) Is In A Good Position To Deliver On Growth Plans

Mar 28

We're Hopeful That Monopar Therapeutics (NASDAQ:MNPR) Will Use Its Cash Wisely

Jul 15

Here's Why We're Not Too Worried About Monopar Therapeutics' (NASDAQ:MNPR) Cash Burn Situation

Mar 26

Finansal Durum Analizi

Kısa Vadeli Yükümlülükler: MNPR 'nin kısa vadeli varlıkları ( $7.2M ) kısa vadeli yükümlülüklerini ( $1.1M ) aşıyor.

Uzun Vadeli Yükümlülükler: MNPR un uzun vadeli yükümlülüğü bulunmamaktadır.

Borç-Özkaynak Tarihçesi ve Analizi

Borç Seviyesi: MNPR borçsuzdur.

Borcun Azaltılması: MNPR un 5 yıl önce borcu yoktu.

Bilanço

Nakit Pist Analizi

Geçmişte ortalama olarak zarar eden şirketler için, en az 1 yıllık nakit akışına sahip olup olmadıklarını değerlendiriyoruz.

İstikrarlı Nakit Pisti: MNPR şirketinin mevcut serbest nakit akışına göre bir yıldan fazla yetecek nakit pisti bulunmaktadır.

Tahmini Nakit Akışı: MNPR un, serbest nakit akışı her yıl % 18.8 oranında tarihi oranda azalmaya devam ederse bir yıldan az nakit akışı süresi vardır

Monopar Therapeutics Bilanço Sağlığı

Finansal Sağlık kriter kontrolleri 5/6

Anahtar bilgiler

Son finansal sağlık güncellemeleri

Monopar Regains Compliance with Nasdaq Minimum Bid Price Rule

We Think Monopar Therapeutics (NASDAQ:MNPR) Needs To Drive Business Growth Carefully

Nasdaq Grants Extension to Monopar Therapeutics to Regain Compliance with the Minimum Bid Price Requirement

Is Monopar Therapeutics (NASDAQ:MNPR) In A Good Position To Deliver On Growth Plans?

Monopar Therapeutics Receives Letter from Nasdaq Regarding Bid Price Requirement

Monopar Therapeutics Receives Letter from Nasdaq Regarding Bid Price Requirement

Recent updates

Monopar Regains Compliance with Nasdaq Minimum Bid Price Rule

Monopar Receives Clearance to Proceed with Phase 1 Therapeutic Trial of Novel Radiopharmaceutical in Advanced Cancers

Monopar Receives Clearance to Proceed with Phase 1 Therapeutic Trial of Novel Radiopharmaceutical in Advanced Cancers

Monopar Therapeutics Inc. Announces Initial Data for First Patient Dosed in Radiopharma Phase 1 Clinical Trial of MNPR-101-Zr

We Think Monopar Therapeutics (NASDAQ:MNPR) Needs To Drive Business Growth Carefully

New major risk - Market cap size

New major risk - Financial position

New major risk - Revenue and earnings growth

Monopar Therapeutics Inc., Annual General Meeting, Aug 05, 2024

Monopar Therapeutics Inc. Announces First Patient Enrolled in First-in-Human Phase 1 Trial for Its Novel Radiopharmaceutical MNPR-101-Zr

Monopar Therapeutics Inc. Announces CFO Changes

Monopar Therapeutics Inc. Announces CFO Changes

Price target decreased by 38% to US$2.08

Monopar Therapeutics Inc. Announces Filing of Patent Protecting MNPR-101 Radiopharma Optimization Findings

Monopar Therapeutics Inc Initiates Radiopharma Phase 1 Clinical Trial for MNPR-101-Zr in Advanced Cancer Patients

Price target decreased by 52% to US$4.05

Monopar Therapeutics Inc. Announces Positive Preclinical Therapeutic Isotope Data for its MNPR-101 Radiopharma Program

Nasdaq Grants Extension to Monopar Therapeutics to Regain Compliance with the Minimum Bid Price Requirement

Is Monopar Therapeutics (NASDAQ:MNPR) In A Good Position To Deliver On Growth Plans?

Monopar Therapeutics Inc. Announces Promising Preclinical Data for its MNPR-101 Radiopharma Program Targeting Advanced Cancers

Monopar Receives Clearance to Proceed with First-In-Human Phase 1 Trial of Novel Radiopharmaceutical MNPR-101-Zr in Advanced Cancers

New major risk - Share price stability

New major risk - Share price stability

Monopar Therapeutics Inc. Presents Data Showing Tumor Reduction Benefit of Camsirubicin from Ongoing Phase 1b at the 2023 Connective Tissue Oncology Society (CTOS) Annual Meeting

Monopar Therapeutics Receives Letter from Nasdaq Regarding Bid Price Requirement

Monopar Therapeutics Receives Letter from Nasdaq Regarding Bid Price Requirement

New major risk - Revenue and earnings growth

New major risk - Revenue and earnings growth

Monopar Therapeutics Inc. Provides Update on Camsirubicin Clinical Trial

New major risk - Market cap size

Monopar Therapeutics Inc. Announces Encouraging Camsirubicin Phase 1b Trial Update

Price target decreased by 49% to US$9.80

Will Monopar Therapeutics (NASDAQ:MNPR) Spend Its Cash Wisely?

Monopar Therapeutics Inc. Announces Camsirubicin Clinical Program Update - Improved Side Effect Profile Seen to Date Compared to Doxorubicin

Monopar Therapeutics Inc. Announces Projected Timeline of Upcoming Quarter 1 2023 Data Events for Validive, Camsirubicin, and MNPR-101 RIT

Price target increased by 12% to US$19.29

Monopar Therapeutics Inc. Announces Successful Advancement of Camsirubicin Phase 1b Clinical Trial Past Fourth Cohort, Escalates Next to 650mg/m2

Monopar Therapeutics Inc. Announces Promising MNPR-202 Data from Ongoing National University of Singapore Collaboration

Monopar Therapeutics Inc. Announces Encouraging Clinical Data from Ongoing Camsirubicin Phase 1B Trial

We Think Monopar Therapeutics (NASDAQ:MNPR) Needs To Drive Business Growth Carefully

Insufficient new directors

Monopar Announces Completion of Phase 2b Enrollment and Commencement of Phase 3 Enrollment in Its Voice Trial for Severe Oral Mucositis

Monopar stock soars 19% as enrollment finishes in phase 2 part of oral mucositis study of Validive

Price target increased to US$32.67

We're Keeping An Eye On Monopar Therapeutics' (NASDAQ:MNPR) Cash Burn Rate

Monopar Therapeutics Inc., Annual General Meeting, Jun 28, 2022

Insufficient new directors

Monopar Therapeutics Announces Resignation of Andrew P. Mazar as Member of the Board of Directors, Effective April 8, 2022

Monopar Therapeutics (NASDAQ:MNPR) Is In A Good Position To Deliver On Growth Plans

Monopar Announces Clinical and Preclinical Program Updates

Price target increased to US$32.67

Monopar Therapeutics Inc. Advances Dosing of Camsirubicin to Higher Level Than Tested In Any Previous Clinical Trial

Price target increased to US$33.33

Monopar Therapeutics Inc. Expands Phase 2b/3 VOICE Clinical Trial to Europe

Monopar Therapeutics Inc. Announces FDA Clearance to Proceed with Camsirubicin Clinical Trial Targeting Advanced Soft Tissue Sarcoma

We're Hopeful That Monopar Therapeutics (NASDAQ:MNPR) Will Use Its Cash Wisely

Monopar Therapeutics Inc. to Present Results from Analysis of Oropharyngeal Cancer Patients in Completed Phase 2 Validive® Trial At MASCC/ISOO

Monopar Therapeutics Inc. and Northstar Medical Radioisotopes Announce Patent Filing on Promising Radiopharmaceutical Discovery

Forecast to breakeven in 2025

Here's Why We're Not Too Worried About Monopar Therapeutics' (NASDAQ:MNPR) Cash Burn Situation

Monopar Therapeutics Inc. Appoints Laura Kelly as Director of Clinical Operations

Monopar Announces First Patient Dosed in Its Phase 2b/3 VOICE Trial Evaluating Validive® for the Prevention of Chemoradiotherapy-Induced Severe Oral Mucositis (SOM) in Oropharyngeal Cancer (OPC)

Monopar Announces Publication Demonstrating Potential Utility of MNPR-101 as an Imaging Agent to Improve Surgical Outcomes in Bladder Cancer

New 90-day high: US$8.51

Price target raised to US$33.33

Monopar nabs U.S. patent covering camsirubicin

Monopar Therapeutics Inc. and NorthStar Medical Radioisotopes, LLC Announces Selection of uPRIT Candidate for Potential Treatment of Severe COVID-19

Monopar Therapeutics selects targeted immuno-therapeutic candidate for COVID-19

New 90-day high: US$5.66